Liver Diseases  >>  ribavirin  >>  Phase 1
Welcome,         Profile    Billing    Logout  

10 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ribavirin / Generic mfg.
NCT02063607: The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients

Completed
1a/1b
60
RoW
Peginterferon lambda
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Hepatitis C
02/15
07/16
NCT00630058: A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C

Completed
1
20
Japan
MP-424(H), PEG-IFN-a-2b, RBV, Telaprevir, MP-424 (L), PEG-IFN-a-2b, RBV
Mitsubishi Tanabe Pharma Corporation, Vertex Pharmaceuticals Incorporated
Hepatitis C
03/09
03/09
NCT00565539: Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection

Completed
1
56
US, Canada
PEGylated recombinant interleukin 29 (PEG-rIL-29), PEGylated interferon lambda (PEG-IFN lambda)
ZymoGenetics
Hepatitis C, Chronic
10/09
10/09
NCT00823862: Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

Completed
1
34
Europe
SD-101, CpG Class C Immunostimulatory Sequence (ISS), TLR9 Agonist, ribavirin
Dynavax Technologies Corporation, Synteract, Inc., PPD
Chronic Hepatitis C
12/09
02/10
NCT00905632: 4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients

Completed
1
75
Europe
BI 207127 middle dose +SOC, BI 207127 high dose+SOC, Placebo + SOC, BI 207127 low dose + SOC
Boehringer Ingelheim
Hepatitis C, Chronic
03/11
 
NCT01185860: A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1

Completed
1
59
Europe, RoW
danoprevir, peginterferon alfa-2a [Pegasys], placebo, ribavirin, ritonavir
Hoffmann-La Roche
Hepatitis C, Chronic
01/12
01/12
NCT01052701: Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment

Completed
1
26
US
Ribavirin, Ribavirin (RBV), Ribavirin plus Abacavir (ABC), RBV + ABC
Johns Hopkins University, GlaxoSmithKline, University of Colorado, Denver
Hepatitis C, HIV
09/12
12/12
NCT01377909: HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity

Terminated
1
20
US
statin
Bader, Ted, M.D.
Chronic Hepatitis C
08/13
08/13
NCT01567540: A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients

Terminated
1
3
Europe
Sitagliptin
Institut National de la Santé Et de la Recherche Médicale, France
Hepatitis C
01/14
01/14
SWIFT-C, NCT02128217: Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection

Checkmark AASLD 2014: C-SWIFT
Oct 2014 - Oct 2014: AASLD 2014: C-SWIFT
Completed
1
44
US
Sofosbuvir, SOF, Ribavirin, RBV, Ledipasvir/Sofosbuvir, LDV/SOF
AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection, Hepatitis
02/17
05/17

Download Options